News Sentiment

COLL sentiment intelligence

Collegium Pharmaceutical Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 33.54 Week of 19 Jun 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

85/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-3.2% over one week, -1.6% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Did Collegium Pharmaceutical’s Profitability Surge and Efficiency Gains Just Shift COLL’s Investment Narrative?

Market Reaction

Balanced read

66/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 85/100 classification
One-week reaction -3.2% Price reacting lower
Trend fit Trend inactive -1.6% over four weeks
Fair value 1.2% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 34
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 16
TradingKey 9
Market source 7
Simply Wall Street 6
simplywall.st 4
GlobeNewswire 2
Stock Traders Daily 1
lwvtexas.org 1

Event Lens

What the news is about

Classified themes
Market update 35
Earnings 10
Deals and strategy 2
Balance sheet 1
Guidance 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
Simply Wall Street Direct company coverage

Did Collegium Pharmaceutical’s Profitability Surge and Efficiency Gains Just Shift COLL’s Investment Narrative?

Collegium Pharmaceutical recently reported strong quarterly results with significant revenue growth and a large increase in net profit, suggesting that operational adjustments are improving earnings. This positive performance, coupled with reaffirmed full-year 2026 revenue guidan

Tone
Positive 74/100
Event
Earnings
Published
21 Jun 2026 05:29
Source
Simply Wall Street
TradingKey Direct company coverage

Collegium Pharmaceutical Inc (COLL) Earnings Forecast: Future EPS & Revenue Growth Estimates

Collegium Pharmaceutical Inc (COLL) has an earnings forecast score of 8.00, ranking 55th in the Pharmaceuticals industry. Analysts have an average target price of $48.00 for COLL, with a consensus of "Buy" based on 6 analysts. The company's expected revenue for the next quarter i

Tone
Positive 74/100
Event
Earnings
Published
19 Jun 2026 02:10
Source
TradingKey
TradingKey Direct company coverage

Collegium Pharmaceutical Inc (COLL) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Collegium Pharmaceutical Inc (COLL), highlighting its current valuation score, market capitalization, and P/E ratio. The company's valuation score is 8.50, ranking 84 out of 157 in the Pharmaceuticals industry, with a P/E ratio of 14

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 02:10
Source
TradingKey
TradingKey Direct company coverage

Collegium Pharmaceutical Inc

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 21:40
Source
TradingKey
TradingKey Direct company coverage

Collegium Pharmaceutical Inc (COLL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed breakdown of Collegium Pharmaceutical Inc's (COLL) revenue by business segment and region, using data updated on April 6. The main revenue drivers are Nucynta IR, Belbuca, and Xtampza ER, with all reported revenue originating from the United State

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 21:40
Source
TradingKey
TradingKey Direct company coverage

Collegium Pharmaceutical Inc (COLL) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Collegium Pharmaceutical Inc (COLL), outlining major institutional holdings and different types of shareholders. It provides a breakdown of the largest shareholders, their proportional ownership, and recent changes in their holdin

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 20:40
Source
TradingKey
Stock Traders Daily Direct company coverage

Trading Systems Reacting to (COLL) Volatility

This article analyzes Collegium Pharmaceutical Inc. (NASDAQ: COLL) volatility using AI models, identifying a mid-channel oscillation pattern and an exceptional 86.1:1 risk-reward setup. It outlines specific position, momentum, and risk-hedging trading strategies, along with multi

Tone
Positive 72/100
Event
Market update
Published
14 Jun 2026 11:39
Source
Stock Traders Daily
Stock Titan Direct company coverage

[Form 4] COLLEGIUM PHARMACEUTICAL, INC Insider Trading Activity

COLLEGIUM PHARMACEUTICAL, INC director Gino Santini exercised stock options to acquire 8,700 shares of common stock at $16.49 per share. Following this transaction, Santini directly holds 112,483 shares of common stock, and the exercised option is fully utilized. The Form 4 filin

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 19:40
Source
Stock Titan
Simply Wall Street Direct company coverage

Collegium Pharmaceutical (Nasdaq:COLL) - Stock Analysis

This report provides an in-depth stock analysis of Collegium Pharmaceutical (Nasdaq:COLL), highlighting its current market valuation, future growth prospects, past performance, and financial health. The company is currently trading 36.7% below its estimated fair value with earnin

Tone
Positive 61/100
Event
Market update
Published
08 Jun 2026 01:38
Source
Simply Wall Street
Simply Wall Street Direct company coverage

COLL: Steady 2026 Earnings Guidance Will Support Undervalued Affordable Medicines Theme

Collegium Pharmaceutical (COLL) has reaffirmed its full-year 2026 earnings guidance, projecting product revenues between US$805 million and US$825 million. Analysts have maintained their price target of US$54.33, indicating that the stock is considered 38.6% undervalued based on

Tone
Positive 71/100
Event
Earnings
Published
08 Jun 2026 01:09
Source
Simply Wall Street
Market source Direct company coverage

Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Collegium Pharmaceutical, Inc. announced that it granted 50,305 restricted stock units (RSUs) to 34 newly hired non-executive employees on June 1, 2026, under its 2026 Inducement Plan. These grants serve as a material inducement for their employment, in accordance with Nasdaq Lis

Tone
Positive 62/100
Event
Market update
Published
07 Jun 2026 15:10
Source
Market source
Simply Wall Street Direct company coverage

COLL - Specialty Pharmaceuticals And Diversified Assets Will Drive Future Success

Collegium Pharmaceutical's fair value has been slightly increased to $54.33, reflecting updated assumptions regarding revenue growth, profit margins, and future P/E levels. The company reaffirmed its 2026 earnings guidance, projecting product revenues between $805 million and $82

Tone
Positive 70/100
Event
Earnings
Published
29 May 2026 21:40
Source
Simply Wall Street
GlobeNewswire Direct company coverage

Collegium to Participate in 2026 Jefferies Global Healthcare Conference

Collegium Pharmaceutical, Inc. will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 1:20 p.m. ET. The company, focused on CNS and pain conditions, will webcast the event live, with a replay available for 90 days. This particip

Tone
Neutral 50/100
Event
Market update
Published
27 May 2026 11:40
Source
GlobeNewswire
Simply Wall Street Direct company coverage

How Strong Q1 Earnings and Executive Departures At Collegium Pharmaceutical (COLL) Have Changed Its Investment Story

Collegium Pharmaceutical reported strong Q1 2026 net income and reaffirmed its full-year product revenue guidance, signaling continued commercial momentum. However, upcoming departures of its Chief Commercial Officer and Chief Medical Officer introduce potential execution risks.

Tone
Positive 66/100
Event
Earnings
Published
21 May 2026 21:10
Source
Simply Wall Street
Simply Wall Street Direct company coverage

COLL: Consistent 2026 Earnings Guidance Will Support Affordable Medicines Theme Upside

Collegium Pharmaceutical's fair value has been slightly increased by analysts, moving from $54.17 to $54.33, driven by updated assumptions in revenue growth, profit margins, and future P/E levels. The company reaffirmed its 2026 earnings guidance for product revenues, net, in the

Tone
Positive 71/100
Event
Earnings
Published
21 May 2026 09:10
Source
Simply Wall Street
Stock Titan Direct company coverage

Collegium (NASDAQ: COLL) director sells 20 shares, holds 83,952

Collegium Pharmaceutical director John Gordon Freund reported selling 20 common shares at $34.05 each on May 18, 2026, in an open-market transaction. Following this sale, he directly holds 83,952 common shares and also has indirect interests in additional shares through affiliate

Tone
Neutral 50/100
Event
Market update
Published
20 May 2026 19:40
Source
Stock Titan
Stock Titan Direct company coverage

Director Nancy Lurker awarded 8,741 RSUs at Collegium (COLL)

Collegium Pharmaceutical director Nancy Lurker was granted 8,741 restricted stock units (RSUs) as part of her compensation, with each RSU representing one share of common stock. These RSUs will vest on the earlier of May 14, 2027, or the company's 2027 annual shareholder meeting,

Tone
Neutral 50/100
Event
Market update
Published
19 May 2026 04:10
Source
Stock Titan
Stock Titan Direct company coverage

Collegium (COLL) director sells shares, exercises options and receives RSU grant

Collegium Pharmaceutical director John Gordon Freund recently sold 4,127 shares of common stock, exercised options for 8,700 shares, and received a grant of 8,741 restricted stock units (RSUs). After these transactions, his direct holdings stand at 83,972 shares, with additional

Tone
Neutral 50/100
Event
Market update
Published
19 May 2026 04:08
Source
Stock Titan
Stock Titan Direct company coverage

Director at Collegium (NASDAQ: COLL) receives 8,741 RSUs in equity award

Collegium director Rita J. Balice-Gordon was granted 8,741 Restricted Stock Units (RSUs), increasing her direct holdings to 61,370 shares. These RSUs vest on the earlier of May 14, 2027, or the company’s 2027 Annual Meeting of Shareholders, provided she continues her service as a

Tone
Neutral 50/100
Event
Market update
Published
19 May 2026 04:08
Source
Stock Titan
Stock Titan Direct company coverage

Collegium Pharmaceutical (COLL) director Donovan Glancy files initial Form 3

Collegium Pharmaceutical (COLL) director Donovan Michael Glancy has filed an initial Form 3, indicating his start as a reporting person for the company. This filing discloses his initial ownership of Collegium Pharmaceutical securities but does not report any transactions or deri

Tone
Neutral 50/100
Event
Market update
Published
19 May 2026 04:08
Source
Stock Titan
Stock Titan Direct company coverage

Director at Collegium (NASDAQ: COLL) awarded 8,741 RSUs in equity grant

Collegium Pharmaceutical director Gino Santini was granted 8,741 restricted stock units (RSUs) on May 14, 2026, as an equity award with a $0.00 purchase price. These RSUs will vest on the earlier of May 14, 2027, or the company's 2027 Annual Meeting of Shareholders, provided he c

Tone
Neutral 50/100
Event
Market update
Published
19 May 2026 04:08
Source
Stock Titan